Podcast interview with Dr. Elvira Müller. EU joint HTA – decided, but how will it be executed and how should companies prepare
In Europe, there are at least as many reimbursement assessment processes in place as European…
Certara2023年2月7日
FDA awards new grants to support developing & assessing complex generic drugs
Certara’s Simcyp physiologically-based pharmacokinetic (PBPK) Simulator is being used to verify and expand biosimulation models…
Certara2023年2月7日
Artificial Intelligence: What is it & how can it accelerate rare disease drug development?
Large & complex information streams present opportunities for the AI data scientist to aid in…
Certara2023年2月3日
Machine learning model selection with Darwin in Pirana
DarwinをPiranaで活用して、機械学習モデルの選択を最適化する方法をご紹介します。Watch this on-demand…
Certara2023年2月3日
Certara to Report Fourth Quarter and Full Year 2022 Financial Results on March 1st, 2023
PRINCETON, N.J.— 2023年2月1日-- Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ（Nasdaq：CERT) はCERT), a global leader in biosimulation, today…
Certara2023年2月1日
How Modeling & Simulation is Addressing the Immunogenicity Challenge: An academic nicety is now a drug development and regulatory differentiator
Learn how modeling and simulation can help drug developers overcome the immunogenicity challenge, a major…
Certara2023年1月30日
